Literature DB >> 2398453

Suppression of delayed-type hypersensitivity to PPD and PHA in elderly HTLV-I carriers.

K Murai1, N Tachibana, S Shioiri, E Shishime, A Okayama, J Ishizaki, K Tsuda, N Mueller.   

Abstract

In a previous study on immune responsiveness among asymptomatic human T-cell leukemia virus type I (HTLV-I) carriers, we found that carriers had significantly reduced delayed-type hypersensitivity (DTH) response to purified protein derivative (PPD) skin testing. The association was strongest among persons at least 60 years of age. In order to evaluate this finding further, we evaluated the response to both PPD and phytohemagglutinin (PHA) in an elderly population. Fifty-six consecutive hospitalized patients with nonimmunosuppressive diseases were examined. None had a history of tuberculosis nor evidence of the known HTLV-I-associated diseases. The subjects' ages ranged from 62-93 years (median = 75 years); 43 were women and 13 were men. Twenty-two of the subjects were HTLV-I antibody positive. Among the carriers, there was an increased level of nonreactivity to PPD, the relative risk adjusted for age (RR) being 1.9 (95% confidence interval, 0.62-5.8), as well as to PHA of RR = 2.3 (0.60-9.0). When subjects were cross-classified for response to both skin tests, 15 of 17 carriers were nonreactive to either or both antigens compared to 15 of 25 noncarriers [RR = 5.1 (0.99-25.9) (p value, one-sided = 0.026)]. The decline in reactivity to both antigens increased with age, but was consistently lower among the carriers. Among subjects with positive reactions to PPD, the degree of reaction as measured by the size of erythema was reduced among the carriers; however, for PHA responders, the response in carriers appeared to be normal. Among the HTLV-I antibody negative subjects, the size of erythema for both antigens was strongly correlated (p = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2398453

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  14 in total

Review 1.  Interference with immune function by HTLV-1.

Authors:  P K C Goon; C R M Bangham
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 2.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

3.  Peripheral blood mononuclear cells from individuals infected with human T-cell lymphotropic virus type 1 have a reduced capacity to respond to recall antigens.

Authors:  Rita Elizabeth Mascarenhas; Cláudia Brodskyn; Geisa Barbosa; Jorge Clarêncio; Antônio Souza Andrade-Filho; Frederico Figueiroa; Bernardo Galvão-Castro; Fernanda Grassi
Journal:  Clin Vaccine Immunol       Date:  2006-05

Review 4.  Clinicopathological features of cryptococcal lymphadenitis and a review of literature.

Authors:  Keisuke Kawamoto; Hiroaki Miyoshi; Takaharu Suzuki; Reiji Muto; Kyohei Yamada; Eriko Yanagida; Mayuko Koshino; Yuya Sasaki; Jun Takizawa; Hirohito Sone; Yasuo Sugita; Masao Seto; Koichi Ohshima
Journal:  J Clin Exp Hematop       Date:  2017-06-08

5.  Modulation of T-cell responses to a recall antigen in human T-cell leukemia virus type 1-infected individuals.

Authors:  M Suzuki; C S Dezzutti; A Okayama; N Tachibana; H Tsubouchi; N Mueller; R B Lal
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

6.  Population differences in immune marker profiles associated with human T-lymphotropic virus type I infection in Japan and Jamaica.

Authors:  Brenda M Birmann; Elizabeth C Breen; Sherri Stuver; Beverly Cranston; Otoniel Martínez-Maza; Kerstin I Falk; Akihiko Okayama; Barrie Hanchard; Nancy Mueller; Michie Hisada
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

7.  HTLV-1 infection is associated with a history of active tuberculosis among family members of HTLV-1-infected patients in Peru.

Authors:  K Verdonck; E González; W Schrooten; G Vanham; E Gotuzzo
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

8.  Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.

Authors:  T J Palker; E R Riggs; D E Spragion; A J Muir; R M Scearce; R R Randall; M W McAdams; A McKnight; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

9.  Viral commensalism in humans?

Authors:  Martin J Blaser; Fred T Valentine
Journal:  J Infect Dis       Date:  2008-07-01       Impact factor: 5.226

10.  Prevalence of human T-cell lymphotropic virus type 1 infection in hospitalized patients with tuberculosis.

Authors:  M de Lourdes Bastos; B Osterbauer; D L Mesquita; C A Carrera; M J Albuquerque; L Silva; D N Pereira; L Riley; E M Carvalho
Journal:  Int J Tuberc Lung Dis       Date:  2009-12       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.